Sep 16,2019

DermEngine & MoleScope | The Value Of The Patient Experience

Every day, new, exciting technologies are released that support medical professionals in providing quality services to their patients. How can their success be measured? Efficacy? Affordability? Quality? All key indicators, there is one important piece of criteria that’s often missed: patient satisfaction. MetaOptima explains how the company keeps the patients in the center throughout every step of the care coordination process.

#ai/software

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 03,2019

White Paper | Intelligent Solutions For Patient-Centric Care

As the rates of skin cancer cases continues to rise at an annual rate of 7.7%, dermatologists, GPs and other medical professionals are unable to meet the growing need for detecting this disease at the earliest possible stage for optimized health outcomes. DermEngine, an intelligent dermatology platform, can support this demand through increasing the accessibility, efficiency, and quality of provided services through features such as its teledermatology feature, clinical decision support tools, communications network, and cross-platform accessibility. Access to the whitepaper from the Company for more information.

View Analyst & Ambassador Comments
Go to original news
Sep 25,2019

Guerbet and IBM Watson Health Announce a Second Co-Development Project as Part of their Strategic Partnership for Leveraging Artificial Intelligence in Medical Imaging

Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and co-commercialize an artificial intelligence (AI) solution to help clinicians diagnose and monitor patients with prostate cancer. This agreement follows the first agreement signed in July 2018 between the two companies with the aim of using an artificial intelligence program to help clinicians diagnose and monitor patients with liver cancer.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 02,2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

RIKEN and Astellas Pharma Inc. announced today that they have entered into a worldwide licensing agreement for the research, development and commercialization of cell therapy formulations applying RIKEN’s artificial adjuvant vector cell technology in oncology. Based on the agreement, Astellas has acquired the rights for the research, development and commercialization of cell therapy formulations applying RIKEN’s aAVC technology that targets selected cancer antigens.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 24,2019

Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

Pfizer and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer’s development of innovative targeted cancer medicines. Under the terms of the agreement, Pfizer will draw on de-identified, real-world datasets and analytical expertise from Flatiron Health to inform development strategies and activities for a number of clinical development projects across major tumor types, as well as jointly explore other innovative ways to drive clinical development innovation with real-world data.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
Sep 16,2019

Harnessing technology to fight toxicities in cancer immunotherapies

In recent years, there has been a drastic change in the treatment landscape of several advanced cancers. Cancer immunotherapies have shown to be a viable treatment option for many patients who would have otherwise had a poor prognosis with traditional treatments, such as chemotherapy. Digital health interventions in detecting immune-related adverse events could be a viable tool to detect the Most immune-mediated adverse events. Based on the patient’s therapy and the historical trend of symptoms, Kaiku Health algorithms are capable of predicting the occurrence of up to 15 symptoms that may indicate the development of immune-related adverse events, such as skin and pulmonary toxicities.

PRODUCT

#ml

View Analyst & Ambassador Comments
Go to original news
Oct 30,2019

MetaOptima Partners With Sonic Healthcare

MetaOptima Technology Australia Pty Ltd has signed a national agreement with Sonic Healthcare to implement the DermEngine software across the Australian Skin Cancer Centres and IPN Family Medical Centres network. DermEngine’s cloud-based solution will provide the Sonic Healthcare Doctors with an intelligent dermatology ecosystem for the imaging, documentation and diagnosis of skin conditions including skin cancer. Powered by artificial intelligence, this smart dermatology platform helps medical professionals manage busy workflows with secure cross-platform access for a targeted focus on enhanced patient outcomes.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 31,2019

AI Predicts which Pre-Malignant Breast Lesions will Progress to Advanced Cancer

New research at Case Western Reserve University could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone. Once a lumpectomy of breast tissue reveals this pre-cancerous tumor, most women have surgery to remove the remainder of the affected tissue and some are given radiation therapy as well, said Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at the Case School of Engineering.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 10,2019

Bayer Inks Deals with Eleven Startups under G4A Digital Health Partnerships Program

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups, including Blackford Analysis, a curated marketplace platform of regulatory-approved medical image analysis apps and AI algorithms for clinical value add. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations to drive forward the development of specific digital solutions to improve patients' health in the fields of cardiovascular diseases, oncology, ophthalmology, pulmonology, radiology as well as digital therapeutics. The participating healthcare startup companies were selected by Bayer from over 750 applications out of 65 countries based on the strategic fit, development stage of the project, and the assessment of internal experts.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 17,2019

Combination of AI & Radiologists more Accurately Identified Breast Cancer

An artificial intelligence (AI) tool - trained on roughly a million screening mammography images - identified breast cancer with approximately 90 percent accuracy when combined with analysis by radiologists, a new study finds. Led by researchers from NYU School of Medicine and the NYU Center for Data Science, the study examined the ability of a type of AI, a machine learning computer program, to add value to the diagnoses reached by a group of 14 radiologists as they reviewed 720 mammogram images.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY